These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

527 related items for PubMed ID: 25471035

  • 1. Advances in systemic therapies for metastatic castration-resistant prostate cancer.
    Pant MK, Abughaban A, Aragon-Ching JB.
    Future Oncol; 2014 Nov; 10(14):2213-26. PubMed ID: 25471035
    [Abstract] [Full Text] [Related]

  • 2. Current management of advanced and castration resistant prostate cancer.
    Gomella LG, Petrylak DP, Shayegan B.
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [Abstract] [Full Text] [Related]

  • 3. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
    Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, Sonpavde G, Sternberg CN, Yegnasubramanian S, Antonarakis ES.
    Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
    [Abstract] [Full Text] [Related]

  • 4. Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics.
    Mukherji D, Omlin A, Pezaro C, Shamseddine A, de Bono J.
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):555-66. PubMed ID: 24452758
    [Abstract] [Full Text] [Related]

  • 5. Castration-resistant prostate cancer: from new pathophysiology to new treatment.
    Sridhar SS, Freedland SJ, Gleave ME, Higano C, Mulders P, Parker C, Sartor O, Saad F.
    Eur Urol; 2014 Feb; 65(2):289-99. PubMed ID: 23957948
    [Abstract] [Full Text] [Related]

  • 6. Improvement in survival and quality of life with new therapeutic agents in metastatic castration-resistant prostate cancer: comparison among the results.
    Recine F, Ceresoli GL, Baciarello G, Cerbone L, Calabrò F.
    Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):400-10. PubMed ID: 26337241
    [Abstract] [Full Text] [Related]

  • 7. Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.
    Bazarbashi S, Bachour M, Bulbul M, Alotaibi M, Jaloudi M, Jaafar H, Mukherji D, Farah N, Alrubai T, Shamseddine A.
    Crit Rev Oncol Hematol; 2014 Apr; 90(1):36-48. PubMed ID: 24289901
    [Abstract] [Full Text] [Related]

  • 8. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
    Bastos DA, Dzik C, Rathkopf D, Scher HI.
    Oncology (Williston Park); 2014 Aug; 28(8):693-9. PubMed ID: 25140626
    [Abstract] [Full Text] [Related]

  • 9. [New therapies in metastatic castration resistant prostate cancer].
    Thibault C, Massard C.
    Bull Cancer; 2015 Jun; 102(6):501-8. PubMed ID: 26022286
    [Abstract] [Full Text] [Related]

  • 10. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.
    Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B, Alcaraz A, Bahl A, Bracarda S, Di Lorenzo G, Efstathiou E, Finn SP, Fosså S, Gillessen S, Kellokumpu-Lehtinen PL, Lecouvet FE, Oudard S, de Reijke TM, Robson CN, De Santis M, Seruga B, de Wit R.
    Eur J Cancer; 2014 Jun; 50(9):1617-27. PubMed ID: 24703899
    [Abstract] [Full Text] [Related]

  • 11. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA, Yen AE, Weigel NL.
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [Abstract] [Full Text] [Related]

  • 12. Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies.
    Kim W, Ryan CJ.
    Cancer; 2015 Feb 01; 121(3):361-71. PubMed ID: 25236176
    [Abstract] [Full Text] [Related]

  • 13. [ASC-J9 for castration-resistant prostate cancer].
    Yamashita S, Arai Y.
    Nihon Rinsho; 2014 Dec 01; 72(12):2126-9. PubMed ID: 25518345
    [Abstract] [Full Text] [Related]

  • 14. Current, new and novel therapy for castration-resistant prostate cancer.
    Gaya JM, Ahallal Y, Sanchez-Salas R, Barret E, Rozet F, Galiano M, Macek P, Durand M, Cerruti J, Prapotnich D, Ropert S, Bennamoun M, Cathelineau X.
    Expert Rev Anticancer Ther; 2013 Jul 01; 13(7):819-27. PubMed ID: 23875660
    [Abstract] [Full Text] [Related]

  • 15. Drug therapies for metastatic castration-resistant prostate cancer.
    El-Bahesh E, Finianos A, Alfaraj A, Aragon-Ching JB.
    Future Oncol; 2015 Jul 01; 11(17):2395-403. PubMed ID: 26274603
    [Abstract] [Full Text] [Related]

  • 16. Current therapeutic options in metastatic castration-resistant prostate cancer.
    Ingrosso G, Detti B, Scartoni D, Lancia A, Giacomelli I, Baki M, Carta G, Livi L, Santoni R.
    Semin Oncol; 2018 Oct 01; 45(5-6):303-315. PubMed ID: 30446166
    [Abstract] [Full Text] [Related]

  • 17. Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.
    Cereda V, Formica V, Massimiani G, Tosetto L, Roselli M.
    Expert Opin Investig Drugs; 2014 Apr 01; 23(4):469-87. PubMed ID: 24490883
    [Abstract] [Full Text] [Related]

  • 18. Sequencing Treatment for Castration-Resistant Prostate Cancer.
    Handy CE, Antonarakis ES.
    Curr Treat Options Oncol; 2016 Dec 01; 17(12):64. PubMed ID: 27822685
    [Abstract] [Full Text] [Related]

  • 19. Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer.
    Pinto Á.
    Cancer Biol Ther; 2014 Feb 01; 15(2):149-55. PubMed ID: 24100689
    [Abstract] [Full Text] [Related]

  • 20. Sequencing systemic therapies in metastatic castration-resistant prostate cancer.
    Liu JJ, Zhang J.
    Cancer Control; 2013 Jul 01; 20(3):181-7. PubMed ID: 23811702
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.